NASDAQ:VERU Veru (VERU) Stock Price, News & Analysis $2.33 -0.05 (-2.10%) As of 09:45 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Veru Stock (NASDAQ:VERU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Veru alerts:Sign Up Key Stats Today's Range$2.31▼$2.3150-Day Range$2.09▼$4.2352-Week Range$2.05▼$7.33Volume3,579 shsAverage Volume934,846 shsMarket Capitalization$37.40 millionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingModerate Buy Company Overview Veru Inc. is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development. The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19. In parallel, Veru is developing toremifene, a selective estrogen receptor modulator repurposed to address chemotherapy-induced side effects and support women’s health applications. The company’s pipeline also encompasses exploratory programs aimed at targeting key drivers of cancer progression and acute inflammatory responses. Founded in 2010 (formerly operating as Veru Healthcare) by Dr. Mark A. Enyedy, who serves as President and Chief Executive Officer, Veru has conducted clinical studies across North America, Europe and Asia. The company maintains collaborations with academic institutions and contract research organizations to execute multi-center trials, and it has secured manufacturing partnerships to support planned commercial supply. Veru’s leadership team combines expertise in pharmaceutical development, regulatory affairs and oncology drug commercialization to guide late-stage program advancement.AI Generated. May Contain Errors. Read More Veru Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreVERU MarketRank™: Veru scored higher than 54% of companies evaluated by MarketBeat, and ranked 424th out of 842 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingVeru has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialVeru has a consensus price target of $23.00, representing about 866.4% upside from its current price of $2.38.Amount of Analyst CoverageVeru has only been the subject of 3 research reports in the past 90 days.Read more about Veru's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Veru are expected to decrease in the coming year, from ($1.07) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veru is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veru is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeru has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Veru's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.96% of the float of Veru has been sold short.Short Interest Ratio / Days to CoverVeru has a short interest ratio ("days to cover") of 1.93, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Veru has recently decreased by 27.68%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVeru does not currently pay a dividend.Dividend GrowthVeru does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Veru this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for VERU on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows6 people have added Veru to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Veru insiders have not sold or bought any company stock.Percentage Held by Insiders14.20% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Veru's insider trading history. Receive VERU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VERU Stock News HeadlinesCritical Comparison: Veru (NASDAQ:VERU) and QuidelOrtho (NASDAQ:QDEL)July 20 at 2:15 AM | americanbankingnews.comPalisade's Dan Veru talks his small cap trading playbookJuly 12, 2026 | cnbc.comThe gold strategy buried in Trump's plans that insiders are already watchingNancy Pelosi's portfolio gained 71 percent in 2024 while the S&P 500 returned just 28 percent. In 2023, she earned 65 percent while the broader market gained 24 percent. Researchers say congressional leaders outperform rank-and-file lawmakers by up to 47 percent annually. Now a new opportunity may dwarf any single stock trade. The U.S. still carries 8,133 tonnes of gold on its books at a price frozen since 1973 - and a single executive order could change that. A free guide called The Great Gold Reset explains how everyday investors can position themselves now.July 20 at 1:00 AM | American Alternative (Ad)Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop DayJuly 7, 2026 | globenewswire.comVeru Establishes At-the-Market Equity Offering ProgramJuly 2, 2026 | tipranks.comVeru to Conduct Enobosarm Clinical Study With Novo Nordisk's Weight-Loss Pill WegovyJune 5, 2026 | marketwatch.comVeru And 2 Other Intriguing Penny Stocks To WatchJune 5, 2026 | finance.yahoo.comVeru (VERU) surges 161.8% after disclosing Novo Nordisk Wegovy supply deal for obesity studyJune 4, 2026 | quiverquant.comQSee More Headlines VERU Stock Analysis - Frequently Asked Questions How have VERU shares performed this year? Veru's stock was trading at $2.14 at the beginning of 2026. Since then, VERU stock has increased by 11.2% and is now trading at $2.38. How were Veru's earnings last quarter? Veru Inc. (NASDAQ:VERU) announced its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.16. Read the conference call transcript. When did Veru's stock split? Veru shares reverse split before market open on Monday, August 11th 2025.The 1-10 reverse split was announced on Wednesday, August 6th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Veru's major shareholders? Top institutional investors of Veru include FNY Investment Advisers LLC (0.65%). Insiders that own company stock include Mitchell Shuster Steiner, Harry Fisch, Michael L Rankowitz and K Gary Barnette. View institutional ownership trends. How do I buy shares of Veru? Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Veru own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veru investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Ford Motor (F), Walt Disney (DIS) and Moderna (MRNA). Company Calendar Last Earnings5/13/2026Today7/20/2026Next Earnings (Estimated)8/11/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6d) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 6 days, VERU's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPersonal Products Current SymbolNASDAQ:VERU CIK863894 Webwww.veruhealthcare.com Phone(305) 509-6897Fax312-595-9122Employees230Year Founded1896Price Target and Rating Average Price Target for Veru$23.00 High Price Target$25.00 Low Price Target$20.00 Potential Upside/Downside+866.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-54.72% Return on Assets-39.09% Debt Debt-to-Equity RatioN/A Current Ratio6.19 Quick Ratio6.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.25 per share Price / Book1.90Miscellaneous Outstanding Shares16,050,000Free Float13,771,000Market Cap$38.20 million OptionableOptionable Beta-1.19 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:VERU) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredEx-CIA Insider: “Prepare for a Mid-Term Meltdown”Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...Paradigm Press | SponsoredSMX: From Under-the-Radar to Must-Watch!SMX (Security Matters) PLC is building Digital Material Passport technology that embeds molecular-level marker...Smallcaps Daily | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veru Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veru With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
